特瑞普利单抗(抗PD-1)对比大剂量干扰素α2b用于已切除黏膜黑色素瘤辅助治疗:一项II期随机试验
该II期随机试验将145例已切除黏膜黑色素瘤患者按1:1随机分配至大剂量干扰素α2b组(n=72)或特瑞普利单抗组(n=73),治疗1年。中位随访26.3个月,两组中位无复发生存期分别为13.6个月和13.9个月,远处无转移生存期风险比1.00(95%CI 0.65-1.54),全因死亡风险比1.11(95%CI 0.66-1.84)。特瑞普利单抗组≥3级治疗中出现的不良事件发生率为27.4%,大剂量干扰素α2b组为87.5%。
要点
- 特瑞普利单抗组与大剂量干扰素α2b组的中位无复发生存期分别为13.6个月和13.9个月。
- 两组远处无转移生存期风险比1.00(95%CI 0.65-1.54),全因死亡风险比1.11(95%CI 0.66-1.84)。
- ≥3级治疗中出现的不良事件发生率特瑞普利单抗组为27.4%,大剂量干扰素α2b组为87.5%。
核心结论
- 特瑞普利单抗显示出与大剂量干扰素α2b相似的无复发生存期和更有利的安全性特征,两者均优于历史数据,提示特瑞普利单抗可能是更好的治疗选择。
- 仍需要额外的转化研究和更好的治疗方案来改善黏膜黑色素瘤的临床结局。
研究设计与样本
- 这是一项II期随机试验,从2017年7月至2019年5月纳入145例已切除的黏膜黑色素瘤患者。
- 患者按1:1随机分配至大剂量干扰素α2b组(n=72)或特瑞普利单抗组(n=73),治疗1年,直至疾病复发/远处转移、不可接受的毒性或撤回知情同意。
- 主要终点为无复发生存期,次要终点包括远处无转移生存期、总生存期和安全性。
主要发现
- 中位随访26.3个月,特瑞普利单抗组与大剂量干扰素α2b组的无复发生存事件数分别为51例和46例,总生存事件数分别为33例和29例,远处无转移生存事件数分别为49例和44例。
- 特瑞普利单抗组和大剂量干扰素α2b组的中位无复发生存期分别为13.6个月(95%CI 8.31-19.02)和13.9个月(95%CI 8.28-19.61)。
- 两组远处无转移生存期无显著差异,风险比1.00(95%CI 0.65-1.54)。
- 特瑞普利单抗组中位总生存期为35.1个月(95%CI 27.93个月-未达到),两组全因死亡无显著差异,风险比1.11(95%CI 0.66-1.84)。
- 特瑞普利单抗组和大剂量干扰素α2b组患者实际输注剂量的中位总和分别为3672 mg和1054.5 MIU。
临床怎么用
- 作者认为,特瑞普利单抗显示出与大剂量干扰素α2b相似的无复发生存期和更有利的安全性特征,提示特瑞普利单抗可能是更好的治疗选择。
- 作者指出,仍需要额外的转化研究和更好的治疗方案来改善黏膜黑色素瘤的临床结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No standard of care for mucosal melanoma (MM) in the adjuvant setting has been established. Meanwhile, relapse-free survival (RFS) is only ∼5 months after surgery alone. This phase II trial aimed to compare toripalimab versus high-dose interferon-α2b (HDI) as an adjuvant therapy for resected MM. PATIENTS AND METHODS: From July 2017 to May 2019, 145 patients with resected MM were randomized (1 : 1) to receive HDI (n = 72) or toripalimab (n = 73) for 1 year until disease relapse/distant metastasis, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. The secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), and safety. RESULTS: After a median follow-up of 26.3 months, the number of RFS, OS, and DMFS events was 51 versus 46, 33 versus 29, and 49 versus 44 in the toripalimab arm and the HDI arm, respectively. The median RFS was 13.6 [95% confidence interval (CI) 8.31-19.02] months and 13.9 (95% CI 8.28-19.61) months in the toripalimab arm and the HDI arm, respectively. The DMFS was not significantly different between the two arms [hazard ratio (HR) 1.00; 95% CI 0.65-1.54]. The median OS was 35.1 months (95% CI 27.93 months-not reached) in the toripalimab arm, with no significant difference in all-cause death (HR 1.11, 95% CI 0.66-1.84) for the two arms. The median sums of the patients' actual infusion doses were 3672 mg and 1054.5 MIU in the toripalimab arm and the HDI arm, respectively. The incidence of treatment-emergent adverse events with a grade ≥3 was much higher in the HDI arm than in the toripalimab arm (87.5% versus 27.4%). CONCLUSIONS: Toripalimab showed a similar RFS and a more favorable safety profile than HDI, both better than historical data, suggesting that toripalimab might be the better treatment option. However, additional translational studies and better treatment regimens are still warranted to improve the clinical outcome of MM.
引用
- Lian B, Si L, Chi ZH, et al. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol. 2022. PMID: 35842199. doi:10.1016/j.annonc.2022.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。